|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07K 16/28 | (2006.01) |
| A61K 39/00 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3377534 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16819718.4 |
| Date of filing the European patent application | 2016-11-18 | |
| (97) | Date of publication of the European application | 2018-09-26 |
| (45) | Date of publication and mention of the grant of the patent | 2025-06-18 |
| (46) | Date of publication of the claims translation | 2025-08-11 |
| (86) | Number | PCT/US2016/062884 |
| Date | 2016-11-18 |
| (87) | Number | WO 2017/087870 |
| Date | 2017-05-26 |
| (30) | Number | Date | Country code |
| 201562257139 P | 2015-11-18 | US | |
| 201662345314 P | 2016-06-03 | US |
| (72) |
FAITH, Nathan E. , US
|
| (73) |
Bristol-Myers Squibb Company ,
Route 206 and Province Line Road, Princeton, NJ 08543,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Plaučių vėžio gydymas, panaudojant anti-PD-1 antikūno ir anti CTLA-4 antikūno derinį |
| TREATMENT OF LUNG CANCER USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY AND AN ANTI-CTLA-4 ANTIBODY |
| Payment date | Validity (years) | Amount | |
| 2025-10-21 | 10 | 231.00 EUR |
| 2026-11-18 |